secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001493152-25-013975
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months
--------------------------------------------------------------------------------

- Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
- 5 of 8 patients continuing without progression; 7 of 9 showed PSA decrease from baseline.
- Trial powered for 45% PFS improvement; actual PFS far exceeded CARD trial benchmark of 3.7-6.7 months.
- No Grade 3/4 toxicities observed; ENV105 well tolerated with standard supportive care.
- Phase 2 trial enrolling at Cedars-Sinai, City of Hope, Huntsman Cancer Center; KOL event held Sept 18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/0001493152-25-013975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer